High-risk neuroblastoma challenges and opportunities for antibody-based cellular immunotherapy Review
| Authors: | Persaud, N. V.; Park, J. A.; Cheung, N. K. V. |
| Review Title: | High-risk neuroblastoma challenges and opportunities for antibody-based cellular immunotherapy |
| Abstract: | Immunotherapy has emerged as an attractive option for patients with relapsed or refractory high-risk neuroblastoma (HRNB). Neuroblastoma (NB), a sympathetic nervous system cancer arising from an embryonic neural crest cell, is heterogeneous clinically, with outcomes ranging from an isolated abdominal mass that spontaneously regresses to a widely metastatic disease with cure rates of about 50% despite intensive multimodal treatment. Risk group stratification and stage-adapted therapy to achieve cure with minimal toxicities have accomplished major milestones. Targeted immunotherapeutic approaches including monoclonal antibodies, vaccines, adoptive cellular therapies, their combinations, and their integration into standard of care are attractive therapeutic options, although curative challenges and toxicity concerns remain. In this review, we provide an overview of immune approaches to NB and the tumor microenvironment (TME) within the clinical translational framework. We propose a novel T cell-based therapeutic approach that leverages the unique properties of tumor surface antigens such as ganglioside GD2, incorporating specific monoclonal antibodies and recent advancements in adoptive cell therapy. © 2024 by the authors. |
| Keywords: | review; multimodality cancer therapy; side effect; t lymphocyte; cohort analysis; monoclonal antibody; membrane antigen; neuroblastoma; ganglioside gd2; adoptive transfer; high risk population; abdominal mass; ex vivo study; therapy; high-risk neuroblastoma; tumor microenvironment; neural crest cell; adoptive cellular therapy; bispecific antibody; cellular immunotherapy; human; nervous system cancer; ex vivo armed t cell with bispecific antibody (eat) |
| Journal Title: | Journal of Clinical Medicine |
| Volume: | 13 |
| Issue: | 16 |
| ISSN: | 2077-0383 |
| Publisher: | MDPI |
| Date Published: | 2024-08-02 |
| Start Page: | 4765 |
| Language: | English |
| DOI: | 10.3390/jcm13164765 |
| PROVIDER: | scopus |
| PMCID: | PMC11355836 |
| PUBMED: | 39200906 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding MSK author is Nai Kong V. Cheung -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work